Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs Co-administration Not Recommended [update]

[update] Healthcare professionals are notified by the FDA that co-administration of Victrelis (boceprevir) with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors is not recommended.  The Victrelis drug label has been revised accordingly.

Background of Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs

Victrelis (boceprevir) is a hepatitis C virus (HCV) protease inhibitor. Ritonavir-boosted HIV protease inhibitors include Kaletra (lopinavir/ritonavir), ritonavir-boosted Prezista (darunavir) and ritonavir-boosted Reyataz (atazanavir).

FDA Alert on Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs

A drug-drug interaction study and clinical trial revealed that co-administration of Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor drugs increased the possibility of their effectiveness reduction. Thus, the amount of HCV or HIV virus in the blood could increase.

AttorneyOne.com is a free nationwide legal referral service. We are not a law firm. We help consumers find the best representation for their legal needs.